Status:
RECRUITING
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
Lead Sponsor:
Yale University
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Eligibility:
FEMALE
40-65 years
Phase:
PHASE2
Brief Summary
This is a phase II, randomized, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs. placebo in reducing moderate to severe vasomotor symptoms (VMS) in breast c...
Detailed Description
This is a phase II, randomized, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs. placebo in reducing moderate to severe vasomotor symptoms (VMS) in breast c...
Eligibility Criteria
Inclusion
- Women with diagnosed, histologically confirmed, clinical stage I-III, HR+ invasive breast cancer as defined by ASCO CAP guidelines for whom adjuvant endocrine therapy would be indicated.
- BMI of 18-38 kg/m2
- Age 40-65
- Currently on endocrine therapy (tamoxifen or aromatase inhibitors)
- Willing and able to provide written informed consent/assent for the trial.
- Postmenopausal as defined by spontaneous amenorrhea for at least 12 consecutive months, spontaneous amenorrhea for at least 6 months with biochemical criteria or menopause (FSH \> 40 IU/L), or bilateral oophorectomy for at least 6 weeks before the screening visit, or if premenopausal chemically suppressed by GnRH agonist therapy with ultrasensitive estradiol level \<10.
- On endocrine therapy for a minimum of 3 months and has planned duration of 12 weeks left in the treatment regimen.
- Experiencing an average of seven or more moderate to severe hot flashes per day over a 7-day period as documented by Symptom Diary during the Screening Period and seeking treatment or relief for VMS.
- Able to swallow oral formulation of the study agent.
Exclusion
- Participants who have a diagnosis of stage IV metastatic disease
- Receiving any other cancer treatment other than endocrine therapy. This includes chemotherapy, targeted therapies, and immunotherapy.
- Receiving cytochrome CYP1A2 inhibitors
- Participants who have received any treatment for vasomotor symptoms (prescription, over the counter, or herbal) for the last 28 days.
- Pregnant or lactating patients
- Active liver disease, jaundice, or elevated liver aminotransferases (ALT or AST) \>2x ULN, or elevated total bilirubin, OR elevated direct bilirubin, or elevated INR, or elevated alkaline phosphatase \>2x ULN
- Creatinine \> 1.5 times upper limit of normal; or estimated GFR ≤ 30 mL/min per 1.73 m2 at screening.
- Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Key Trial Info
Start Date :
December 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT06917313
Start Date
December 5 2025
End Date
March 1 2028
Last Update
December 24 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States, 06511
2
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43201